Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSCORE
2018-002250-79Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and relatlimab in colorectal cancer (CRC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Disease control rate at 6 months. Status: unknown.
02
Drugs
nivolumabrelatlimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2018-002250-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002250-79.